Ignite Creation Date:
2025-12-25 @ 12:23 AM
Ignite Modification Date:
2026-05-17 @ 2:35 PM
Study NCT ID:
NCT00853658
Status:
COMPLETED
Last Update Posted:
2016-11-25
First Post:
2009-02-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Heart Failure | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Chronic Heart Failure | View |
| None | Cardiovascular death | View |
| None | CHF hospitalization | View |
| None | morbi-mortality trial | View |
| None | outcome study | View |
| None | endpoint driven | View |
| None | plasma renin activity | View |
| None | renin angiotensin aldosterone system | View |
| None | direct renin inhibitors | View |
| None | BNP | View |
| None | KCCQ | View |
| None | eGFR | View |
| None | (NYHA class II to IV) with elevated | View |
| None | BNP and reduced LVEF | View |